Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer

Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 datasets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations.